Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03006926 · ClinicalTrials.gov registry record · Phase 1
A Trial of Lenvatinib Plus Pembrolizumab in Participants With Hepatocellular Carcinoma
A Phase 1 study, sponsored by Eisai Co..
- Completed
- Registry status
- Phase 1
- Development phase
- 104
- Enrollment target
NCT03006926: Completed Phase 1 study, sponsored by Eisai Co..
NCT03006926 is a Phase 1 study that has completed, run by Eisai Co.. The registered enrollment target is 104 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (73% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03006926, a Phase 1 study, has completed, sponsored by Eisai Co..
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 104 participants
- Enrollment target
Study Summary
This is an open-label Phase 1b study designed to evaluate the tolerability and safety of lenvatinib in combination with pembrolizumab in participants with hepatocellular carcinoma (HCC). The study will evaluate objective response rate and duration of response by modified Response Evaluation Criteria In Solid Tumors (mRECIST) for HCC and Response Evaluation Criteria In Solid Tumors (RECIST 1.1) based on independent imaging review (IIR).
Primary Outcome
A TEAE was defined as an adverse event (AE) that emerged during the time from the first dose of study drug to 120 days (if participant initiated new anticancer therapy) following last dose of study drug, was absent at pretreatment (Baseline) or reemerged during treatment, was at pretreatment (Baseline) but stopped before treatment or worsened in severity during treatment relative to the pretreatment state, when AE was continuous. An SAE was any untoward medical occurrence that at any dose: resul
Interventions
- DRUG lenvatinib
- DRUG pembrolizumab (200 mg)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 104 participants |
| Start Date | 2017-02-13 |
| Est. Completion | 2022-11-22 |
| Phase | Phase 1 |
What the finished NCT03006926 record still lists
NCT03006926 is an interventional study that assigns participants to a tested intervention. The registered 104 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (73% higher).
The record links to 0 conditions, and to 2 interventions - of which lenvatinib is the first listed.
NCT03006926 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03006926 about?
NCT03006926 is a clinical study titled "A Trial of Lenvatinib Plus Pembrolizumab in Participants With Hepatocellular Carcinoma". This is an open-label Phase 1b study designed to evaluate the tolerability and safety of lenvatinib in combination with pembrolizumab in participants with hepatocellular carcinoma (HCC). The study will evaluate objective response rate and duration of response by modified Response Evaluation Criteria...
What is the current status of trial NCT03006926?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 104 participants. The study started on 2017-02-13. Estimated completion is 2022-11-22.
What interventions are being tested in trial NCT03006926?
The interventions under investigation include: lenvatinib (DRUG), pembrolizumab (200 mg) (DRUG).
Who is sponsoring clinical trial NCT03006926?
This trial is sponsored by Eisai Co., which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03006926's enrollment target sits among peer trials
104 536th of 2000 higher than 1,460 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03403686 · 104 participants
Liver X Receptor (LXR) as a Novel Therapeutic Target in Diabetic Retinopathy (DR)
- NCT04228367 · 104 participants · NA
JuggerStitch Post Market Clinical Follow-up Study
- NCT04268849 · 104 participants · Phase 3
Trial of IV vs Oral Iron Treatment of Iron Deficiency Anemia in the Post-Operative Bariatric Surgical Patient
- NCT04390724 · 104 participants
Optimizing Y90 Therapy for Radiation Lobectomy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI